Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2010

View Archived Issues

Correlation between genetic variations in Lp(a) lipoprotein and risk of CAD identified

Crystal structure of PI3Kdelta in complex with inhibitors allows design of enhanced agents

Novo Nordisk: 2009 in review

Rexahn provides update on goals for 2010

Nippon Shinyaku and Actelion enter into license agreement on novel PAH therapeutic

Biodegradable nanocarriers with drug delivery and imaging properties described as theranostic agents

Otonomy receives FDA clearance for trial in Meniere's disease

Pulmonary blood density measured by MRI may be used in PAH and heart failure prognosis

Javelin receives FDA PDUFA date for Dyloject NDA for pain

Ligand reports discovery of dual AT1/ETA receptor antagonists

Roche presents novel CCR2 antagonists

Cardiac reserve index differentiates heart failure patients from healthy subjects

Marcadia Biotech initiates phase I trial of MAR-701

Genfit reports the identification of novel PPAR agonists

Georgetown University discloses MLCP inhibitors for cancer therapy

Merck KGaA discloses novel SphK1 and Met kinase inhibitors

MorphoSys and Galapagos add another antibody target to alliance in bone and joint diseases

TD2 and Rondaxe sign alliance to help emerging companies develop cancer therapeutics

BioMimetic completes submission of PMA to FDA for Augment Bone Graft

Biogen and Biovitrum restructure collaboration agreement for rFVIIIFc and rFIXFc

Michael J. Fox Foundation funds research into LRRK2 gene

Hollis-Eden Pharmaceuticals becomes Harbor BioSciences

FDA issues complete response letter for GSK's Horizant in RLS

Pharmasset updates progress of RG-7128 studies

Pivotal Research adds U.S. center to phase II study of VA-111913 for dysmenorrhea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...